Popular Science Honors Innovative Verisante Aura(TM) Skin Cancer Detection Device with "Best of What's New" Award

MY NOTE: Those who have read this blog over time, know that Verisante, is no longer involved with THz, (although it is the former T-Ray Science, which was involved in developing THz for cancer detection). Rather Verisante is involved with multispectral scanning. I am an investor in the company.




VANCOUVER, BRITISH COLUMBIA--(Marketwire -11/16/11)- Verisante Technology, Inc. (TSX-V: VRS.V - News)(OTCQX: VRSEF.PK - News)(PINK SHEETS: VRSEF)(Frankfurt: V3T.F - News) (the "Company" or "Verisante"), a leader in cancer imaging technology, announced today that the editors of Popular Science magazine have named Verisante's Aura™ device for skin cancer detection as a top technology innovation of 2011, receiving one of the magazine's coveted "Best of What's New" Awards.
"For 24 years, Popular Science has honored the innovations that surprise and amaze us - those that make a positive impact on our world today and challenge our views of what's possible in the future," said Mark Jannot, Editor-in-Chief of Popular Science. "The Best of What's New Award is the magazine's top honor, and the 100 winners - chosen from among thousands of entrants - represent the highest level of achievement in their fields."
Thomas Braun, President and CEO of Verisante Technology, Inc., said Verisante is honored to be recognized by Popular Science as a company that is making revolutionary advancements in the detection of skin cancer.
"This award is a validation of the hard work and dedication of our employees, consultants, and partners who have come together to make the commercialization of this life-saving device possible," he said. "We are pleased that our commitment to innovation and the exceptional work done by the BC Cancer Agency to develop the Verisante Aura™ is being internationally recognized."
Early detection is key to saving the lives of melanoma patients and saving healthcare costs. When melanoma is diagnosed and treated in the earliest stages, the survival rate is 99 per cent and it costs about $1,800 to treat it. In the late stages, the survival rate decreases to 15 per cent, while the cost to treat it increases to $170,000. The Aura™ will aid medical professionals in the assessment of suspect skin lesions for diagnosis as either skin cancer or a benign disorder in less than two seconds.
Verisante Aura™, a non-invasive optical system, is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy.
The Popular Science issue containing the winners of the Best of What's New Awards is now on sale.
About Best of What's New
Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year; breakthrough products and technologies that represent a significant leap in their categories. The winners - the Best of What's New - are awarded inclusion in the much anticipated
December issue of Popular Science, the most widely read issue of the year since the debut of Best of What's New in 1987. Best of What's New Awards are presented to 100 new products and technologies in 11 categories.